ALH-L1005 attenuates endotoxin induced inner ear damage.

[1]  L. Strojný,et al.  Antiproliferative and Antiangiogenic Properties of Horse Chestnut Extract , 2013, Phytotherapy research : PTR.

[2]  C. Jang,et al.  Matrix metalloproteinase inhibitor attenuates cochlear lateral wall damage induced by intratympanic instillation of endotoxin. , 2012, International journal of pediatric otorhinolaryngology.

[3]  Fu-xiang Ran,et al.  β‐Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells , 2011, Molecular carcinogenesis.

[4]  B. Aggarwal,et al.  Escin, a Pentacyclic Triterpene, Chemosensitizes Human Tumor Cells through Inhibition of Nuclear Factor-κB Signaling Pathway , 2010, Molecular Pharmacology.

[5]  S. Leib,et al.  Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis , 2010, BMC infectious diseases.

[6]  D. Preciado,et al.  The Role of Inflammatory Mediators in the Pathogenesis of Otitis Media and Sequelae , 2008, Clinical and experimental otorhinolaryngology.

[7]  Kensuke Watanabe,et al.  Morphological changes in the inner ear induced by bacterial endotoxin , 1995, Medical Electron Microscopy.

[8]  E. Mackenzie,et al.  VEGF-Induced BBB Permeability is Associated with an MMP-9 Activity Increase in Cerebral ischemia: Both Effects Decreased by ANG-1 , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  A. Karsan,et al.  Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NF-kappaB and c-Jun N-terminal kinase. , 2003, Blood.

[10]  G. Rosenberg.  Matrix Metalloproteinases and Neuroinflammation in Multiple Sclerosis , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[11]  M. I. Lomax,et al.  Gene Expression Profiles of the Rat Cochlea, Cochlear Nucleus, and Inferior Colliculus , 2002, Journal of the Association for Research in Otolaryngology.

[12]  C. Sirtori.  Aescin: pharmacology, pharmacokinetics and therapeutic profile. , 2001, Pharmacological research.

[13]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[14]  T. Sadowski,et al.  Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1 , 2001, Inflammation Research.

[15]  M Chopp,et al.  VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. , 2000, The Journal of clinical investigation.

[16]  A. Reiner,et al.  Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.

[17]  S. Juhn,et al.  Effects of Inflammatory Mediators on Middle Ear Pathology and on Inner Ear Function , 1997, Annals of the New York Academy of Sciences.

[18]  E. Bombardelli,et al.  Aesculus hippocastanum L. , 1996 .

[19]  L. Matrisian.  The matrix‐degrading metalloproteinases , 1992, Journal of neuro-oncology.

[20]  V. Perry,et al.  The acute inflammatory response to lipopolysaccharide in cns parenchyma differs from that in other body tissues , 1992, Neuroscience.

[21]  T. Morizono,et al.  Middle ear inflammatory mediators and cochlear function. , 1991, Otolaryngologic clinics of North America.

[22]  D. Lim,et al.  Endotoxin permeability through the round window. , 1989, Acta oto-laryngologica. Supplementum.

[23]  S. Hellström,et al.  Inner ear disturbances following inoculation of endotoxin into the middle ear. , 1989, Acta oto-laryngologica.

[24]  S. Juhn,et al.  Nature of Blood-Labyrinth Barrier in Experimental Conditions , 1981, The Annals of otology, rhinology, and laryngology.